Market Place
Sourcing Support
All News #Library
Biotech
TLX101-Px (Pixlumi®) MAA Accepted in Europe
30 Apr 2026 //
GLOBENEWSWIRE
Plus Therapeutics, SpectronRx Partner for REYOBIQ Trial
23 Apr 2026 //
GLOBENEWSWIRE
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial
14 Apr 2026 //
GLOBENEWSWIRE
FDA Accepts NDA for TLX101-Px (Pixclara)
09 Apr 2026 //
GLOBENEWSWIRE
ProstACT Global Ph 3 Study (Part 1) Achieves Primary Objectives
09 Mar 2026 //
GLOBENEWSWIRE
First U.S. Patient Dosed In BiPASS Phase 3 Prostate Cancer Study
16 Jan 2026 //
GLOBENEWSWIRE
TLX250-CDx Affects Care For Almost Half With Indeterminate Masses
19 Nov 2025 //
GLOBENEWSWIRE
TLX250-CDx Included in International Guidelines for Renal Imaging
23 Oct 2025 //
GLOBENEWSWIRE
Telix Initiates SOLACE Trial For Metastatic Bone Pain
22 Oct 2025 //
GLOBENEWSWIRE
GAIASO Appoints Dr. Tracey Brown as CEO
16 Sep 2025 //
INDPHARMAPOST
Telix Pharmaceuticals Provides Regulatory Update for TLX250-CDx
28 Aug 2025 //
PHARMAWEB
Telix FAP-targeting Therapeutic in Thyroid Journal Shows Efficacy
07 May 2025 //
GLOBENEWSWIRE
FDA Accepts BLA For TLX250-CDx (Zircaix) For Kidney Cancer Imaging
27 Feb 2025 //
PR NEWSWIRE
Telix Acquires Next-Gen Therapeutic Assets, Innovative Platform
30 Jan 2025 //
GLOBENEWSWIRE
Telix To Acquire ImaginAb Assets & Technology Platform
12 Jan 2025 //
PR NEWSWIRE
Telix Files TLX250-CDx BLA for Kidney Cancer Imaging
29 Dec 2024 //
GLOBENEWSWIRE
First Patient Dosed In CA-NINE Trial For Kidney Cancer Detection
03 Oct 2024 //
GLOBENEWSWIRE
Cullinan Approved to Start Phase 1 Trial of CLN-978
17 Sep 2024 //
GLOBENEWSWIRE
Telix`s ZIRCON Trial For Kidney Cancer Published In Lancet
10 Sep 2024 //
GLOBENEWSWIRE
Telix`s ZIRCON Trial Published In The Lancet Oncology
10 Sep 2024 //
PR NEWSWIRE
Telix Completes Zircaix BLA Submission For Kidney Cancer Imaging
02 Jun 2024 //
GLOBENEWSWIRE
Telix Announces Positive rPFS Data For TLX591 In Prostate Cancer Trial
30 May 2024 //
GLOBENEWSWIRE
Telix Submits BLA for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
18 Dec 2023 //
PR NEWSWIRE
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept
17 Apr 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.